Generally, the CD4/CD8 ratio tends to be lower in tumor patients than in healthy persons, while we observed an increase in the CD4/CD8 ratio in solid tumor patients following decitabine treatment (Figure 4A). This evidence concerns the gene CD8A and neoplasm.